{"schema_version":"secwatch.filing_event.v1","accession":"0001213900-26-099700","form_type":"8-K","ticker":"INMB","cik":"0001711754","company_name":"Inmune Bio, Inc.","filed_at":"2026-09-14T20:05:41+00:00","discovered_at":"2026-09-14T20:07:02.558382+00:00","generated_at":"2026-09-14T20:07:34.710396+00:00","sec_items":["5.02","8.01","9.01"],"event_type":"leadership","sentiment":"positive","materiality_score":0.5,"calibrated_materiality_score":0.5,"confidence":"high","headline":"INmune Bio appoints Sanofi rare-disease GM and biopharma BD veteran to board","bullets":["Board appointed R. Duane Clark II (Sanofi rare-disease GM) and James Sapirstein (CEO of Cocrystal) as independent directors.","Each director gets option for 100,000 shares (36-month vest) plus $50,000 annual cash retainer.","Board enlarged to seven; both join Nominating and Corporate Governance Committee.","Appointments target rare-disease commercialization for Ebstrocel and strategic partnering across pipeline."],"urls":{"canonical":"https://secwatch.observer/filing/0001213900-26-099700","json":"https://secwatch.observer/filing/0001213900-26-099700.json","markdown":"https://secwatch.observer/filing/0001213900-26-099700.md","text":"https://secwatch.observer/filing/0001213900-26-099700.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1711754/000121390026099700/0001213900-26-099700-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1711754/000121390026099700/ea0305404-8k_inmune.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-09-14T20:07:34.710396+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}